Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2013

Open Access 01-12-2013 | Research article

Association between delayed initiation of adjuvant CMF or anthracycline-based chemotherapy and survival in breast cancer: a systematic review and meta-analysis

Authors: Ke-Da Yu, Sheng Huang, Jia-Xin Zhang, Guang-Yu Liu, Zhi-Ming Shao

Published in: BMC Cancer | Issue 1/2013

Login to get access

Abstract

Background

Adjuvant chemotherapy (AC) improves survival among patients with operable breast cancer. However, the effect of delay in AC initiation on survival is unclear. We performed a systematic review and meta-analysis to determine the relationship between time to AC and survival outcomes.

Methods

PubMed, EMBASE, Cochrane Database of Systematic Reviews, and Web-of-Science databases (between January-1 1978 and January-29, 2013) were searched for eligible studies. Hazard ratios (HRs) for overall survival (OS) and disease-free survival (DFS) from each study were converted to a regression coefficient (β) corresponding to a continuous representation per 4-week delay of AC. Most used regimens of chemotherapy in included studies were CMF (cyclophosphamide, methotrexate, and fluorouracil) or anthracycline-based. Individual adjusted β were combined using a fixed-effects or random-effects model depending on heterogeneity.

Results

We included 7 eligible studies with 9 independent analytical groups involving 34,097 patients, 1 prospective observational study, 2 secondary analyses in randomized trials (4 analytical groups), and 4 hospital-/population-based retrospective study. The overall meta-analysis demonstrated that a 4-week increase in time to AC was associated with a significant decrease in both OS (HR = 1.15; 95% confidence interval [CI], 1.03-1.28; random-effects model) and DFS (HR = 1.16; 95% CI, 1.01-1.33; fixed-effects model). One study caused a significant between-study heterogeneity for OS (P < 0.001; I2 = 75.4%); after excluding that single study, there was no heterogeneity (P = 0.257; I2 = 23.6%) and the HR was more significant (HR = 1.17; 95% CI, 1.12-1.22; fixed-effects model). Each single study did not fundamentally influence the positive outcome and no evidence of publication bias was observed in OS.

Conclusions

Longer time to AC is probably associated with worse survival in breast cancer patients.
Appendix
Available only for authorised users
Literature
1.
Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, Cutter D, Darby S, McGale P, Taylor C: Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012, 379 (9814): 432-444.CrossRefPubMed
2.
Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ: Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011, 22 (8): 1736-1747. 10.1093/annonc/mdr304.CrossRefPubMedPubMedCentral
3.
Fedewa SA, Ward EM, Stewart AK, Edge SB: Delays in adjuvant chemotherapy treatment among patients with breast cancer are more likely in African American and Hispanic populations: a national cohort study 2004–2006. J Clin Oncol. 2010, 28 (27): 4135-4141. 10.1200/JCO.2009.27.2427.CrossRefPubMed
4.
Samur M, Bozcuk HS, Dalmaz G, Karaveli S, Köseoğlu FG, Colak T, Pestereli E: Treatment delay in breast cancer; does it really have an impact on prognosis?. Turk J Canc. 2002, 32 (4): 138-147.
5.
Kerbrat P, Roche H, Fumoleau P, Bonneterre J, Romestaing P, Fargeot P, Namer M, Monnier A, Montcuquet P, Goudier M: Does time interval between surgery and adjuvant chemotherapy initiation modify treatment efficacy in operable, breast cancer patients? French Adjuvant Study Group (FASG) Results. J Clin Oncol. 2005, 23 (16S): 660-
6.
Hershman DL, Wang X, McBride R, Jacobson JS, Grann VR, Neugut AI: Delay of adjuvant chemotherapy initiation following breast cancer surgery among elderly women. Breast Canc Res Treat. 2006, 99 (3): 313-321. 10.1007/s10549-006-9206-z.CrossRef
7.
Lohrisch C, Paltiel C, Gelmon K, Speers C, Taylor S, Barnett J, Olivotto IA: Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol. 2006, 24 (30): 4888-4894. 10.1200/JCO.2005.01.6089.CrossRefPubMed
8.
Pronzato P, Campora E, Amoroso D, Bertelli G, Botto F, Conte PF, Sertoli MR, Rosso R: Impact of administration-related factors on outcome of adjuvant chemotherapy for primary breast cancer. Am J Clin Oncol. 1989, 12 (6): 481-485. 10.1097/00000421-198912000-00004.CrossRefPubMed
9.
Colleoni M, Bonetti M, Coates AS, Castiglione-Gertsch M, Gelber RD, Price K, Rudenstam CM, Lindtner J, Collins J, Thurlimann B: Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group. J Clin Oncol. 2000, 18 (3): 584-590.PubMed
10.
Cold S, During M, Ewertz M, Knoop A, Moller S: Does timing of adjuvant chemotherapy influence the prognosis after early breast cancer? Results of the Danish Breast Cancer Cooperative Group (DBCG). Br J Canc. 2005, 93 (6): 627-632. 10.1038/sj.bjc.6602734.CrossRef
11.
DerSimonian R, Laird N: Meta-analysis in clinical trials. Contr Clin Trials. 1986, 7 (3): 177-188. 10.1016/0197-2456(86)90046-2.CrossRef
12.
Larsson SC, Orsini N, Wolk A: Vitamin B6 and risk of colorectal cancer: a meta-analysis of prospective studies. JAMA. 2010, 303 (11): 1077-1083. 10.1001/jama.2010.263.CrossRefPubMed
13.
Biagi JJ, Raphael MJ, Mackillop WJ, Kong W, King WD, Booth CM: Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis. JAMA. 2011, 305 (22): 2335-2342. 10.1001/jama.2011.749.CrossRefPubMed
14.
Yu KD, Di GH, Fan L, Wu J, Hu Z, Shen ZZ, Huang W, Shao ZM: A functional polymorphism in the promoter region of GSTM1 implies a complex role for GSTM1 in breast cancer. FASEB J. 2009, 23 (7): 2274-2287. 10.1096/fj.08-124073.CrossRefPubMed
15.
Berlin JA, Longnecker MP, Greenland S: Meta-analysis of epidemiologic dose–response data. Epidemiology. 1993, 4 (3): 218-228. 10.1097/00001648-199305000-00005.CrossRefPubMed
16.
Johnson ES, Lanes SF, Wentworth CE, Satterfield MH, Abebe BL, Dicker LW: A metaregression analysis of the dose–response effect of aspirin on stroke. Arch Intern Med. 1999, 159 (11): 1248-1253. 10.1001/archinte.159.11.1248.CrossRefPubMed
17.
Higgins JP, Thompson SG: Quantifying heterogeneity in a meta-analysis. Stat Med. 2002, 21 (11): 1539-1558. 10.1002/sim.1186.CrossRefPubMed
18.
19.
Egger M, Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997, 315 (7109): 629-634. 10.1136/bmj.315.7109.629.CrossRefPubMedPubMedCentral
20.
Nurgalieva ZZ, Franzini L, Morgan RO, Vernon SW, Liu CC, Du XL: Impact of timing of adjuvant chemotherapy initiation and completion after surgery on racial disparities in survival among women with breast cancer. Med Oncol. 2013, 30 (1): 419-CrossRefPubMed
21.
Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C: Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med. 1995, 332 (14): 901-906. 10.1056/NEJM199504063321401.CrossRefPubMed
22.
Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, Ingle JN, Cooper MR, Hayes DF, Tkaczuk KH: Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003, 21 (6): 976-983. 10.1200/JCO.2003.02.063.CrossRefPubMed
23.
Levine MN, Bramwell VH, Pritchard KI, Norris BD, Shepherd LE, Abu-Zahra H, Findlay B, Warr D, Bowman D, Myles J: Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1998, 16 (8): 2651-2658.PubMed
24.
French Adjuvant Study Group: Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol. 2001, 19 (3): 602-611.
25.
Heppner GH: In vitro studies on cell-mediated immunity following surgery in mice sensitized to syngeneic mammary tumors. Int J Canc. 1972, 9 (1): 119-125.CrossRef
26.
Fisher B, Gunduz N, Coyle J, Rudock C, Saffer E: Presence of a growth-stimulating factor in serum following primary tumor removal in mice. Canc Res. 1989, 49 (8): 1996-2001.
27.
Fisher B, Gunduz N, Saffer EA: Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. Canc Res. 1983, 43 (4): 1488-1492.
28.
Buzdar AU, Smith TL, Powell KC, Blumenschein GR, Gehan EA: Effect of timing of initiation of adjuvant chemotherapy on disease-free survival in breast cancer. Breast Canc Res Treat. 1982, 2 (2): 163-169. 10.1007/BF01806452.CrossRef
29.
Shannon C, Ashley S, Smith IE: Does timing of adjuvant chemotherapy for early breast cancer influence survival?. J Clin Oncol. 2003, 21 (20): 3792-3797. 10.1200/JCO.2003.01.073.CrossRefPubMed
30.
Jara Sanchez C, Ruiz A, Martin M, Anton A, Munarriz B, Plazaola A, Schneider J, Martinez del Prado P, Alba E, Fernandez-Aramburo A: Influence of timing of initiation of adjuvant chemotherapy over survival in breast cancer: a negative outcome study by the Spanish Breast Cancer Research Group (GEICAM). Breast Canc Res Treat. 2007, 101 (2): 215-223. 10.1007/s10549-006-9282-0.CrossRef
31.
Alkis N, Durnali AG, Arslan UY, Kocer M, Onder FO, Tokluoglu S, Celenkoglu G, Muallaoglu S, Utkan G, Ulas A: Optimal timing of adjuvant treatment in patients with early breast cancer. Med Oncol. 2011, 28 (4): 1255-1259. 10.1007/s12032-010-9566-4.CrossRefPubMed
32.
Brooks RJ, Jones SE, Salmon SE: Improved outcome with early treatment in an adjuvant breast cancer program. Proc Am Soc Clin Oncol. 1983, 2: 110-
33.
Altundag MK, Celik I, Ozisik Y: Is there a range of time for initiation of adjuvant chemotherapy in patients with malignancy?. Ann Oncol. 2000, 11 (9): 1209-10.1023/A:1008339804441.CrossRefPubMed
34.
Biagi JJ, Raphael M, King WD, Kong W, Booth CM, Mackillop WJ: The effect of delay in time to adjuvant chemotherapy (TTAC) on survival in breast cancer (BC): A systematic review and meta-analysis. J Clin Oncol. 2011, 29 (suppl): abstr 1128-
35.
Yu KD, Jiang YZ, Chen S, Cao ZG, Wu J, Shen ZZ, Shao ZM: Effect of large tumor size on cancer-specific mortality in node-negative breast cancer. Mayo Clin Proc. 2012, 87 (12): 1171-1180. 10.1016/j.mayocp.2012.07.023.CrossRefPubMedPubMedCentral
36.
Folkman J: What is the evidence that tumors are angiogenesis dependent?. J Natl Canc Inst. 1990, 82 (1): 4-6. 10.1093/jnci/82.1.4.CrossRef
Metadata
Title
Association between delayed initiation of adjuvant CMF or anthracycline-based chemotherapy and survival in breast cancer: a systematic review and meta-analysis
Authors
Ke-Da Yu
Sheng Huang
Jia-Xin Zhang
Guang-Yu Liu
Zhi-Ming Shao
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2013
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-13-240

Other articles of this Issue 1/2013

BMC Cancer 1/2013 Go to the issue

Research article

Expression of a LINE-1 endonuclease variant in gastric cancer: its association with clinicopathological parameters

Research article

Connexin-43 can delay early recurrence and metastasis in patients with hepatitis B-related hepatocellular carcinoma and low serum alpha-fetoprotein after radical hepatectomy

Research article

Claudin 1 expression in basal-like breast cancer is related to patient age

Research article

Using Twitter for breast cancer prevention: an analysis of breast cancer awareness month

Research article

p53-independent early and late apoptosis is mediated by ceramide after exposure of tumor cells to photon or carbon ion irradiation

Research article

Incidence of pneumonia and risk factors among patients with head and neck cancer undergoing radiotherapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits